Insights

Strategic Acquisition Planet OrganOx has undergone significant ownership changes with Terumo acquiring OrganOx in 2025 for roughly $1.5B and JBIC funding the transaction. This indicates a strong strategic interest from global medical device players in advanced organ preservation, presenting sales opportunities through Terumo's distribution and integration channels as well as potential collaboration with OEM partners to expand global reach.

Global Expansion The acquisition by Terumo and the presence of a robust offshore funding arrangement point to accelerated international deployment of OrganOx technology. Prospects exist for multi-region sales strategies, including integration with Terumo’s existing sales networks, regional service agreements, and training programs to scale adoption of the metra device and related perfusion solutions.

Technological Edge OrganOx’s Normothermic Machine Perfusion technology enables functional organ preservation and objective organ assessment. This creates near-term opportunities to position compatible consumables, service contracts, diagnostic extensions, registries, and value-based offerings around extended preservation times, potentially increasing transplant success rates for hospitals and transplant centers.

Public market signals Public disclosures show high growth expectations with substantial revenue and a clear exit path, suggesting customers in advanced transplant programs may prioritize proven, scalable systems. Sales conversations can emphasize reliability, regulatory readiness, and post-acquisition support from Terumo to alleviate procurement risk and secure longer-term contracts.

Strategic Partnerships The platform’s long development history and university origins highlight potential for collaboration with major research hospitals, academic medical centers, and life science investors. Opportunities exist to offer joint pilots, clinical studies, and bundled training to secure higher adoption rates in high-value transplant centers and generate recurring revenue through service and upgrade packages.

Similar companies to OrganOx

OrganOx Tech Stack

OrganOx uses 8 technology products and services including iCIMS, Databricks, HashiCorp Terraform, and more. Explore OrganOx's tech stack below.

Media & News

OrganOx's Email Address Formats

OrganOx uses at least 1 email format:
OrganOx Email FormatsExamplePercentage
First.Last@organox.comJohn.Doe@organox.com
100%

Frequently Asked Questions

What is OrganOx's phone number?

Minus sign iconPlus sign icon
You can contact OrganOx's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is OrganOx's official website and social media links?

Minus sign iconPlus sign icon
OrganOx's official website is organox.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does OrganOx generate?

Minus sign iconPlus sign icon
As of October 2026, OrganOx's annual revenue is estimated to be $25M - $50M.

What is OrganOx's NAICS code?

Minus sign iconPlus sign icon
OrganOx's NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does OrganOx have currently?

Minus sign iconPlus sign icon
As of October 2026, OrganOx has approximately 249 employees across 4 continents, including Europe, North America and Africa. Key team members include Chief Executive Officer: C. M., Chief Executive Officer & President: N. I. and Chief Financial Officer: B. M. Explore OrganOx's employee directory with LeadIQ.

What industry does OrganOx belong to?

Minus sign iconPlus sign icon
OrganOx operates in the Medical Equipment Manufacturing industry.

What technology does OrganOx use?

Minus sign iconPlus sign icon
OrganOx's tech stack includes iCIMS, Databricks, HashiCorp Terraform, Docker, Mimecast, Google Cloud, DocuSign and Smartsheet.

What is OrganOx's email format?

Minus sign iconPlus sign icon
OrganOx's email format typically follows the pattern of First.Last@organox.com. Find more OrganOx email formats with LeadIQ.

How much funding has OrganOx raised to date?

Minus sign iconPlus sign icon
As of October 2026, OrganOx has raised $207M in funding. The last funding round occurred on Feb 24, 2025 for $160M.

When was OrganOx founded?

Minus sign iconPlus sign icon
OrganOx was founded in 2008.
OrganOx logo

OrganOx

Medical Equipment ManufacturingEngland, United Kingdom201-500 Employees

OrganOx Limited is a medical equipment manufacturer based in Oxford, England, United Kingdom, at 3500 John Smith Drive, OX4 2WB. The company was founded in April 2008 as a spin-out from the University of Oxford, with founders Professors Peter Friend and Constantin Coussios. It develops the OrganOx metra, a portable automated system that perfuses livers outside the body to preserve them under near-physiological conditions and enable functional assessment during transport. OrganOx operates in the medical equipment manufacturing industry and employs between 201 and 500 people. In October 2025, Terumo Medical Corporation completed its acquisition of OrganOx Limited for approximately $1.5 billion, and in June 2026 the former CEO departed with a venture partner from Amadeus Capital joining the firm.

Section iconCompany Overview

Phone number
NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Founded
2008
Employees
201-500

Section iconFunding & Financials

  • $207M

    OrganOx has raised a total of $207M of funding over 9 rounds. Their latest funding round was raised on Feb 24, 2025 in the amount of $160M as a Venture Round.

  • $25M - $50M

    OrganOx's revenue is estimated to be in the range of $25M - $50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.